Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
TMA Precision Health›
Website
AddedFeb 17, 2024
UpdatedJun 18, 2026
TMA Precision Health

TMA Precision Health

TMA Precision Health: Enhancing lives with genome sequencing for rare disease treatment.

HQ
Boston, MA, US
Founded
2019
Loading
Overview
Compare
Fundraising
Employees
Website

TMA Precision Health - Website

An index of every page on tmaprecisionhealth.com, by section.

8 pages across 3 sections · Updated Jul 16, 2026·

Homepage

TMA Precision Health's front door: current positioning and top-line messaging.

sunstonehealth.com

ContactEmployers: Book a demo

Sales, support, and partnership channels for reaching TMA Precision Health directly.

sunstonehealth.com/contact

Blognews

Product updates, deep-dives, and company thinking: TMA Precision Health's 6-post archive.

sunstonehealth.com/news
  • February 3, 2026A Weekend of Hope: Reflections from Epilepsy Awareness Day 2025Marking a significant milestone at Epilepsy Awareness Day at Disneyland, TMA Precision Health offered families on-site genomic testing for the first time to aid in their diagnostic journeys. The team reflected on the profound impact of connecting with the community, returning with a renewed commitment to accelerating insights and expanding access to care.off-site
  • February 3, 2026Partnerships That Amplify a Mission: Collaboration Is the Strongest Path ForwardIn traditional industries, partnerships often start with contracts and metrics. But in healthcare, there’s a famous saying that “health moves at the speed of trust.” It’s especially true in rare diseases, where alignment comes first. One in every nine people faces a genetic condition, a statistic that underscores just how broad and interconnected this challenge is. Addressing it requires collaboration across every corner of the healthcare ecosystem.off-site
  • October 29, 2025Why We Started The Sunstone Health PodcastAbout ten years ago, I was working as a biomedical engineer at the Wyss Institute at Harvard Medical School. I had built technology, published research, and even won awards for some of that work. But then something happened at home that changed everything.‍ My son, Shiloh, was about 18 months old when he started getting sick. Every three or four weeks, out of nowhere, he’d spike these massive fevers, 105, sometimes 106 degrees, that would last for days. We’d rush him to the ER over and over again. Every parent knows how terrifying it is when your child is burning up in your arms, and the doctors can’t give you a real answer.off-site
  • October 29, 2025TMA Precision Health: Turning a Father’s Journey into a Revolution in Rare Disease CareAt TMA Precision Health, healthcare isn’t just a process, it’s a mission to bring clarity, speed, and compassion to families navigating complex medical conditions. This mission is deeply personal for Josh Resnikoff, CEO and co-founder of TMA, whose own experience as a father inspired the company’s founding. Josh’s son, Shiloh, faced a relentless cycle of unexplained fevers and uncertainty that no doctor could quickly resolve. What should have been routine care turned into a long, exhausting “diagnostic odyssey.” Frustrated by the slow, fragmented, and costly healthcare system, Josh realized there had to be a better way, one that could provide families like his with faster answers and actionable guidance.off-site
  • October 29, 2025Building a Better Future for Rare Disease Families: How TMA Precision Health Is Changing the SystemFor most families, navigating healthcare can be stressful. For those touched by a rare disease, it can feel impossible. Endless appointments, inconclusive tests, and unclear diagnoses, each step adding to the emotional and financial toll. For Joshua Resnikoff, CEO and founder of TMA Precision Health, this struggle was deeply personal. His son’s rare disease diagnosis set him on a mission not just to find answers, but to transform how families access care.off-site